BIOMAT Database Logo BIOMAT Database Logo

Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia. 2010

Li Zhang, and Zheng Gang Zhang, and Ben Buller, and James Jiang, and Yanting Jiang, and Danping Zhao, and Xianshuang Liu, and Dan Morris, and Michael Chopp
Henry Ford Health System, Department of Neurology, 2799 West Grand Boulevard, Detroit, MI 48202, USA. lzhang@neuro.hfh.edu

OBJECTIVE Treatment with a selective proteasome inhibitor, VELCADE, in combination with tissue plasminogen activator (tPA) extended the therapeutic window to 6 hours in young rats after stroke. However, stroke is a major cause of death and disability in the elderly. The present study investigated the effect of VELCADE in combination with a low-dose tPA on aged rats after embolic stroke. METHODS Male Wistar rats at the age of 18 to 20 months were treated with VELCADE (0.2 mg/kg) alone, a low-dose tPA (5 mg/kg) alone, combination of VELCADE and tPA, or saline 2 hours after embolic middle cerebral artery occlusion. To test the contribution of endothelial nitric oxide synthase to VELCADE-mediated neuroprotection, endothelial nitric oxide synthase knockout and wild-type mice were treated with VELCADE (0.5 mg/kg) 2 hours after embolic stroke. RESULTS Treatment with VELCADE significantly reduced infarct volume, whereas tPA alone did not reduce infarct volume and aggravated blood-brain barrier disruption in aged rats compared with saline-treated rats. However, the combination treatment significantly enhanced the reduction of infarct volume, which was associated with an increase in endothelial nitric oxide synthase activity compared with saline-treated rats. Additionally, the combination treatment promoted thrombolysis and did not increase the incidence of hemorrhage transformation. VELCADE significantly reduced lesion volume in wild-type mice but failed to significantly reduce lesion volume in endothelial nitric oxide synthase knockout mice. CONCLUSIONS Treatment with VELCADE exerts a neuroprotective effect in aged rats after stroke. The combination of VELCADE with the low-dose tPA further amplifies the neuroprotective effect. Endothelial nitric oxide synthase at least partly contributes to VELCADE-mediated neuroprotection after stroke.

UI MeSH Term Description Entries
D008297 Male Males
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D011719 Pyrazines A heterocyclic aromatic organic compound with the chemical formula C4H4N2. Pyrazine
D001897 Boronic Acids Inorganic or organic compounds that contain the basic structure RB(OH)2. Boronic Acid,Acid, Boronic,Acids, Boronic
D002545 Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION. Cerebral Ischemia,Ischemic Encephalopathy,Encephalopathy, Ischemic,Ischemia, Cerebral,Brain Ischemias,Cerebral Ischemias,Ischemia, Brain,Ischemias, Cerebral,Ischemic Encephalopathies
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D000069286 Bortezomib A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA. LDP-341,PS 341,PS-341,Velcade,341, PS,LDP 341,LDP341,PS341
D000375 Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. Senescence,Aging, Biological,Biological Aging

Related Publications

Li Zhang, and Zheng Gang Zhang, and Ben Buller, and James Jiang, and Yanting Jiang, and Danping Zhao, and Xianshuang Liu, and Dan Morris, and Michael Chopp
Annexin A2 Plus Low-Dose Tissue Plasminogen Activator Combination Attenuates Cerebrovascular Dysfunction After Focal Embolic Stroke of Rats.
December 2017, Translational stroke research,
Li Zhang, and Zheng Gang Zhang, and Ben Buller, and James Jiang, and Yanting Jiang, and Danping Zhao, and Xianshuang Liu, and Dan Morris, and Michael Chopp
Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats.
March 2013, Stroke,
Li Zhang, and Zheng Gang Zhang, and Ben Buller, and James Jiang, and Yanting Jiang, and Danping Zhao, and Xianshuang Liu, and Dan Morris, and Michael Chopp
Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats.
December 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism,
Li Zhang, and Zheng Gang Zhang, and Ben Buller, and James Jiang, and Yanting Jiang, and Danping Zhao, and Xianshuang Liu, and Dan Morris, and Michael Chopp
Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats.
March 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism,
Li Zhang, and Zheng Gang Zhang, and Ben Buller, and James Jiang, and Yanting Jiang, and Danping Zhao, and Xianshuang Liu, and Dan Morris, and Michael Chopp
Low-dose tissue plasminogen activator.
December 2003, Journal of cataract and refractive surgery,
Li Zhang, and Zheng Gang Zhang, and Ben Buller, and James Jiang, and Yanting Jiang, and Danping Zhao, and Xianshuang Liu, and Dan Morris, and Michael Chopp
Antiactin-targeted immunoliposomes ameliorate tissue plasminogen activator-induced hemorrhage after focal embolic stroke.
August 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism,
Li Zhang, and Zheng Gang Zhang, and Ben Buller, and James Jiang, and Yanting Jiang, and Danping Zhao, and Xianshuang Liu, and Dan Morris, and Michael Chopp
Thrombolysis with low dose tissue plasminogen activator.
December 1992, Archives of disease in childhood,
Li Zhang, and Zheng Gang Zhang, and Ben Buller, and James Jiang, and Yanting Jiang, and Danping Zhao, and Xianshuang Liu, and Dan Morris, and Michael Chopp
Effects of ML351 and tissue plasminogen activator combination therapy in a rat model of focal embolic stroke.
May 2021, Journal of neurochemistry,
Li Zhang, and Zheng Gang Zhang, and Ben Buller, and James Jiang, and Yanting Jiang, and Danping Zhao, and Xianshuang Liu, and Dan Morris, and Michael Chopp
Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator.
August 2003, Stroke,
Li Zhang, and Zheng Gang Zhang, and Ben Buller, and James Jiang, and Yanting Jiang, and Danping Zhao, and Xianshuang Liu, and Dan Morris, and Michael Chopp
Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia.
September 2005, Stroke,
Copied contents to your clipboard!